Review: evidence is incomplete on the benefits and risks of commonly used herbal medicines


QUESTION: What are the benefits and risks of commonly used herbal medicines?

Data sources
Systematic reviews were identified by searching Medline, EMBASE/Excerpta Medica, CISCOM, AMED, and the Cochrane Library (from inception to October 2000), and by contacting experts.

Study selection
Systematic reviews were selected if they included randomised controlled trials (RCTs) done in humans on ginkgo, St John's wort, ginseng, echinacea, saw palmetto, or kava.

Data extraction
Data were extracted on the common and manufacturer names and uses of each herbal medicinal product, type and quality of the systematic reviews, sample sizes, and results.

Main results
2 reviews (of adequate and good quality) of ginkgo showed positive effects on memory impairment, although these results are questionable because of the possibility of publication bias. 2 reviews (of adequate to good quality) of ginkgo showed beneficial effects in dementia. 1 adequate quality review of ginkgo for tinnitus also had questionable results because of the lack of rigorous trials. 1 good quality review of ginkgo for intermittent claudication showed that ginkgo led to moderate and probably clinically relevant increases in pain free walking distances. Ginkgo’s adverse effects were usually mild, transient, and reversible.

Several good quality reviews showed that St John’s wort was more effective than placebo for mild to moderate depression. 1 meta-analysis of 14 RCTs showed that St John’s wort was more effective than placebo (relative benefit 1.9, 95% CI 1.2 to 2.8) and similar to tricyclic antidepressants (relative benefit 1.2, CI 1.0 to 1.4) for depressive disorders. However, St John’s wort may interact with several prescription drugs (eg, anticoagulants, oral contraceptives, and antiviral agents), which may have clinically serious consequences.

1 adequate quality review showed that ginseng was not beneficial as a sedative, hypnotic, demulcent, aphrodisiac, antidepressant, or diuretic agent. 1 good quality review showed that echinacea may be effective in preventing and treating upper respiratory tract infections, but trial data are not rigorous or conclusive.

1 good quality review showed that saw palmetto might reduce symptoms of benign prostatic hyperplasia (eg, nocturia and peak urinary flow) in the short term. Adverse effects of saw palmetto were rare and mild. 1 adequate quality review showed that kava might have short term effectiveness in treating anxiety; serious adverse effects of kava were rare.

Conclusions
Evidence suggests that St John’s wort may be effective in mild to moderate depression, although the effects may be overestimated. Data from weak studies suggest that echinacea may be effective in preventing and treating upper respiratory tract infections. Saw palmetto may have short term effectiveness in benign prostatic hyperplasia, and kava may have short term effectiveness in anxiety treatment. Data on ginkgo show positive effects for dementia and intermittent claudication, but are questionable for cognitive function and tinnitus. Ginseng is not beneficial for a variety of conditions. Overall, evidence is incomplete on the benefits and risks of these commonly used herbal medicines.

COMMENTARY
In 1998, Eisenburg et al reported that use of herbal treatments had increased 380% from 1990 to 1997 and that 1 in 5 people who were taking prescription drugs were also taking herbs, high dose vitamins, or both.1 The well done review by Ernst assessed the efficacy and safety of herbal treatments. The quality of included studies was evaluated, and weak trials were identified. Ernst notes that publication bias was a factor in the evaluation of ginkgo for cognitive function (excluding dementia), and echinacea for the treatment and prevention of upper respiratory tract infections. St John’s wort appears to be efficacious for mild to moderate depression despite methodological flaws in earlier studies.

The field of herbal treatments is ever changing and Ernst’s challenge that physicians “acquire sufficient knowledge in this area to advise their patients responsibly” is a challenge for all healthcare providers. Furthermore, most patients do not disclose their use of herbal products or complementary treatments to their healthcare providers.1 New data on the safety of herbal products continue to be reported, including a recent warning that approximately 25 reports of liver toxicity in Germany and Switzerland have been associated with kava use.2

Interactions between herbal treatments and other drugs are a serious concern. Also, because of the low quality of existing studies, many interactions may not be recognised. Ernst highlights other safety issues, including the lack of quality control and standardisation of herbal treatments that pose risks from contamination, underdosing, or both. Rigorous studies are needed to identify adverse effects and inherent dangers associated with the combined use of prescription drugs and herbal products. If one is to use herbal products, only those brands found to be effective in clinical trials should be used. Herbal remedies need to be further evaluated before practitioners can adequately assess risk-benefit ratios.

Diane Wardell, RNC, PhD
Associate Professor
School of Nursing, University of Texas Houston
Houston, Texas, USA


Review: evidence is incomplete on the benefits and risks of commonly used herbal medicines

Evid Based Nurs 2002 5: 80
doi: 10.1136/ebn.5.3.80

Updated information and services can be found at:
http://ebn.bmj.com/content/5/3/80

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://ebn.bmj.com/content/5/3/80#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Other anaesthesia (45)
- Prostate (14)
- Prostate cancer (14)
- Urological cancer (16)
- Complementary medicine (70)
- Drugs: musculoskeletal and joint diseases (152)
- Dementia (96)
- Drugs: cardiovascular system (269)
- Ear, nose and throat/otolaryngology (60)
- Memory disorders (psychiatry) (124)
- TB and other respiratory infections (122)
- Pain (neurology) (312)
- Contraception (45)
- Drugs: infectious diseases (241)
- Drugs: obstetrics and gynaecology (44)
- Internet (387)
- Mood disorders (including depression) (84)
- Reproductive medicine (335)
- Stroke (219)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/